Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FT 819

Next Previous
Drug Profile

FT 819

Alternative Names: 1XX CAR19 T-cell therapy - Fate Therapeutics; FT 8198; FT-819; hiPSC-derived TCR-less TRAC-CAR19 T cells - Fate Therapeutics

Latest Information Update: 21 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Fate Therapeutics
  • Class Anti-inflammatories; Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I B-cell lymphoma; Chronic lymphocytic leukaemia; Myositis; Precursor B-cell lymphoblastic leukaemia-lymphoma; Systemic lupus erythematosus; Systemic scleroderma; Vasculitis

Most Recent Events

  • 21 Oct 2025 FT 819 is still in phase I trial Precursor-B-cell-lymphoblastic-leukaemia-lymphoma, Chronic-lymphocytic-leukaemia, B-cell lymphoma (Monotherapy, Combination therapy, Second-line therapy or greater) in USA (Parenteral) (NCT04629729)
  • 12 Aug 2025 Efficacy data from a phase-I trial in Systemic lupus erythematosus released by Fate Therapeutics
  • 12 Aug 2025 Fate Therapeutics plans a registrational trial in Systemic Lupus Erythematosus and refractory Lupus Nephritis in 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top